A Phase 2 Randomized, Double-blind Pilot Study of IL-17-Targeting with 2 Secukinumab in Moderate-to-Severe Atopic Dermatitis

This randomized, double-blind, phase 2 study aimed to investigate the efficacy and safety of secukinumab as compared to placebo in 41 subjects with moderate-to-severe AD over a 16-week period, with evaluations of clinical outcomes and molecular and cellular profiles in skin. Overall design: Trial Design: Randomized, double-blind, placebo-controlled pilot study Participants: Chronic moderate-to-severe atopic dermatitis (AD patients)>18 years Interventions: Secukinumab 300mg subcutaneous vs. placebo Objective: To evaluate the efficacy of secukinumab in moderate-to-severe intrinsic or extrinsic A Primary outcome: change in epidermal thickness of lesional skin at Week 16 Randomization: Patients were randomized to secukinumab or placebo 2:1 Blinding: Participants, care givers, and those assessing outcomes were blinded to treatment arm